Therapeutics/Diagnostics News

The ACG and AGA have released a joint clinical practice guideline with 10 evidence-based recommendations for the pharmacological management of adults with chronic idiopathic constipation, the first to include magnesium oxide and senna.

The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.

The FDA granted Intercept Pharmaceuticals orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate intended for treatment of patients with primary biliary cholangitis.

CHICAGO — In a Healio video exclusive, Glenn S. Tillotson, MSc, PhD, discusses the safety and sustained efficacy of Rebyota at 6 months for recurrent Clostridioides difficile infection in patients with immunocompromising conditions.

CHICAGO — Individuals aged 45 to 49 years who were mailed fecal immunochemical tests for colorectal cancer screening completed the tests in a timelier manner than those aged 50 years and older, according to data from Digestive Disease Week.

CHICAGO — Digital gut-directed hypnotherapy resulted in greater improvement in abdominal pain and stool symptoms in patients with irritable bowel syndrome compared with digital muscle relaxation, according to research.

CHICAGO — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, recaps results from a real-world analysis of Zinplava for prevention of recurrent Clostridioides difficile infection in patients with congestive heart failure.

CHICAGO — A diet rich in sweetened candy or drinks, exposure to antibiotics during early childhood and urban living were among risk factors for developing pediatric inflammatory bowel disease, according to data at Digestive Disease Week.

CHICAGO — In this Healio video, Evan S. Dellon, MD, MPH, explains that while mepolizumab outperformed placebo at 3 months, there were no additional symptom or endoscopic improvements at 6 months in patients with eosinophilic esophagitis.

CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video.